Clinical Trials · NCT02075606

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

CompletedPhase 4Lanreotide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Ipsen
Enrollment
50
Start date
May 2014
Locations
14 sites, United Kingdom
Primary endpoint
Assessment of Clinical Symptomatic Response
View Lanreotide compound reference